Abstract:
AIM:To describe the overall survival, progression-free survival, response rate and toxicity of pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer. METHODS:A retrospective study of 45 patients with recurrent or progressive ovarian cancer was conducted at the Westmead Cancer Care Centre. Patients received PLD at a starting dose of 30-50 mg/m(2) every 4 weeks. RESULTS:A total of 43 patients were included for analysis. The starting dose was 40 mg/m(2) in 67% of cases, and 21 % had a dose increase. A median of 2 cycles (mean 3, range 1-7) was given. All patients were assessable for response and 77% stopped treatment due to progressive disease. The overall response rate to PLD assessed by CA-125 criteria was 14 percent (six of 43 patients). Five patients (12 percent) were from the potentially platinum-sensitive group and one (2 percent) was from the platinum-resistant group. The overall median progression-free survival was 52 days (2 months), which was greater in the platinum-sensitive than in the platinum-resistant group (4.4 months vs 1.7 months, respectively, P = 0.030). The median overall survival was 296 days (10.6 months) with a trend for this to be longer in the platinum-sensitive than in the platinum-resistant group (13 vs 9 months, P = 0.393). Overall 25 percent of patients had grade 2 or 3 toxicity. CONCLUSION:The benefit of PLD in platinum-resistant recurrent ovarian cancer is small and the treatment has considerable toxicity. These data support the need to establish whether chemotherapy in this setting has any favorable effect on quality of life. The Australian New Zealand Gynaecological Oncology Group is currently addressing this question in a large prospective study measuring both the subjective and objective benefit (response and survival) of palliative chemotherapy in platinum-resistant or refractory ovarian cancer in Australia. Clinicians are urged to enter their patients in this study to address this important question.
journal_name
Asia Pac J Clin Oncoljournal_title
Asia-Pacific journal of clinical oncologyauthors
Dear RF,Gao B,Harnett Pdoi
10.1111/j.1743-7563.2009.01263.xsubject
Has Abstractpub_date
2010-03-01 00:00:00pages
66-73issue
1eissn
1743-7555issn
1743-7563pii
AJCO1263journal_volume
6pub_type
杂志文章abstract:AIM:Survival rates for patients with cancer who live in rural and regional areas are worse than in metropolitan areas. This may be due to geographical isolation, delayed diagnosis, inadequate transport, lower socioeconomic status and workforce shortages. We conducted a qualitative study of rural patients, carers and he...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12014
更新日期:2013-09-01 00:00:00
abstract:AIM:To investigate the association between plasma visfatin levels and risk of early and advanced colorectal cancer (CRC). METHODS:In total, 358 CRC patients and 286 controls were enrolled. According to the T factor of the TNM system. cancer patients were divided into two subgroups: early and advanced cancer. Levels of...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12090
更新日期:2016-03-01 00:00:00
abstract:AIMS:Cyclophosphamide was widely used as a single agent prior to the advent of platinum-based regimens for epithelial ovarian cancer, and, in combination with platinum, prior to the adoption of platinum and paclitaxel as standard first-line therapy. As cyclophosphamide currently has no defined role in ovarian cancer we...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12074
更新日期:2016-03-01 00:00:00
abstract:AIM:To evaluate predictive factors which associated with oncological outcomes to first-line axitinib for metastatic renal cell carcinoma (mRCC). METHODS:A retrospective chart review was conducted patients who had been treated with axitinib as first-line therapy for the treatment of mRCC from September 2013 to February...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.13323
更新日期:2020-08-01 00:00:00
abstract:AIM:Elevated neutrophil-to-lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients treated with first-line EGFR tyrosi...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12273
更新日期:2017-10-01 00:00:00
abstract:AIM:Colorectal cancer (CRC) is one of the most common malignancies worldwide and adjuvant chemotherapy is proven to improve survival in patients with Dukes' C CRC. The purpose of this study was to analyze factors influencing referral to medical oncology in patients with Dukes' C colonic cancer in our institutions. MET...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/j.1743-7563.2010.01312.x
更新日期:2010-09-01 00:00:00
abstract:AIM:For early-stage breast cancer, four cycles of docetaxel and cyclophosphamide (TC) was proven superior to doxorubicin plus cyclophosphamide in the US Oncology 9375 trial. Given primary prophylactic antibiotics, 5% febrile neutropenia was recorded in a population comprising 75.5% Caucasians. Smaller trials and retros...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12682
更新日期:2017-12-01 00:00:00
abstract:AIM:To examine the treatment practices for cancer pain relief and adverse event management, and the factors related to patient outcomes in the participating countries/regions. METHODS:The study was a cross-sectional survey conducted between September and December 2013 in 10 countries/regions across Asia. Adult patient...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章,多中心研究
doi:10.1111/ajco.12696
更新日期:2018-06-01 00:00:00
abstract:BACKGROUND:Azacitidine safety and efficacy were established in studies of mainly Caucasian patients. Differences in drug metabolism enzymes between Caucasian and East Asian populations prevent extrapolation of drug effects between these groups. This phase 2 study evaluated azacitidine safety, efficacy and pharmacokinet...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章,多中心研究
doi:10.1111/ajco.12835
更新日期:2018-06-01 00:00:00
abstract:BACKGROUND:Providing appropriate educational resources to patients with head and neck cancer (HNC) is important but challenging. The aim of this study was to determine Australian clinicians' perceptions of currently used HNC information resources. METHODS:A purpose-designed questionnaire was disseminated electronicall...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12858
更新日期:2018-10-01 00:00:00
abstract:AIM:For several decades urinary arylsulfatase (ARS) activity has been reported to be elevated in many cancers. It has been shown that urinary ARS activity may serve as a marker of tumor progression and therapy surveillance. This study was designed to evaluate the clinical application of detection of urinary ARS activit...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/j.1743-7563.2012.01545.x
更新日期:2012-12-01 00:00:00
abstract:AIMS:Esophageal cancer (EC) is one of the most prevalent and deadly cancers worldwide. Along with nutrition, smoking and alcohol consumption, human papillomavirus (HPV) infection is one of the major risk factors, which is modulated by host immune response. This study is aimed at elucidating how HPV modifies host immune...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12135
更新日期:2014-03-01 00:00:00
abstract:AIM:A proportion of locally advanced rectal cancer patients who receive neoadjuvant chemoradiotherapy (NACRT) are still unresectable. This study was undertaken to assess the outcomes of giving additional chemotherapy to rectal cancer patients with unresectable disease after NACRT. METHODS:Patients with poor response t...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12660
更新日期:2017-08-01 00:00:00
abstract:BACKGROUND:Access to palliative care services is essential for attaining universal health coverage for patients with a terminal cancer. Despite this, many patients with advanced cancer in low-income countries, such as Myanmar, suffer at the end of life (EOL) due to little or no access to palliative care. However, actua...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章,多中心研究
doi:10.1111/ajco.13373
更新日期:2020-12-01 00:00:00
abstract:AIM:A viable and sustainable medical oncology profession is integral for meeting the increasing demand for quality cancer care. The aim of this study was to explore the workforce-related experiences, perceptions and career expectations of early-career medical oncologists in Australia. METHODS:A mixed-methods design, i...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12844
更新日期:2018-10-01 00:00:00
abstract:AIMS:To determine the feasibility of stereotactic body radiotherapy (SBRT) in patients with pelvic sidewall recurrence of uterine cervical cancer after radical hysterectomy or definitive radiotherapy. METHODS:We retrospectively reviewed 23 patients with locally recurrent uterine cervical cancer limited to the pelvic s...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12185
更新日期:2016-06-01 00:00:00
abstract:AIM:To carry out a nationwide study of KRAS testing in metastatic colorectal cancer as reported by nine major molecular pathology service providers in Australia, including mutation frequencies and turnaround times that might impact on patient care. METHODS:Participating laboratories contributed information on KRAS mut...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12201
更新日期:2014-09-01 00:00:00
abstract:BACKGROUND:Docetaxel is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC); however, many patients experience febrile neutropenia (FN) and cease treatment early due to toxicity. It is not known whether lower dose (LD) q3-weekly docetaxel impacts toxicity or efficacy. METHODS:Multicenter r...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章,多中心研究
doi:10.1111/ajco.12840
更新日期:2018-10-01 00:00:00
abstract::Posterior reversible encephalopathy syndrome (PRES) is a neuro-radiological syndrome characterized by seizures, altered level of consciousness and visual disturbance. PRES is associated with hyperintense lesions on magnetic resonance imaging (MRI) most commonly seen in the posterior regions. In most cases symptoms and...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章,评审
doi:10.1111/j.1743-7563.2012.01544.x
更新日期:2012-06-01 00:00:00
abstract:BACKGROUND:An elevated preoperative aspartate aminotransferase-to-lymphocyte ratio index (ALRI) may predict poor survival in various cancers. However, the prognostic value of aminotransferase-to-lymphocyte ratio index (ALRI) in patients with hepatocellular carcinoma (HCC) remains to be determined. MATERIALS AND METHOD...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.13458
更新日期:2020-10-30 00:00:00
abstract:AIM:Behavioral interventions such as exercise may induce epigenetic changes. Only few studies investigated the effects of exercise on epigenetic alterations in colorectal cancer survivors. The aim of this study was to explore the changes of genome-wide DNA methylation after 6-week exercise training in colorectal cancer...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.13482
更新日期:2020-10-13 00:00:00
abstract:AIM:Important factors typically associated with prognosis in brain metastases include Karnofsky performance status (KPS), extracranial or cerebellar localization and combination chemotherapy. However, few studies investigated the prognostic role of leptomeningeal metastases (LM) following whole brain radiotherapy (WBRT...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12597
更新日期:2017-10-01 00:00:00
abstract:AIM:Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were established in mainly Caucasian populations. Because of inter-ethnic genotype variability of drug-metabolizing enzymes, it is important to evaluate azacitidine in populations expected to use the drug. METHODS:In this ...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12659
更新日期:2017-10-01 00:00:00
abstract:AIM:This multicenter, observational study aimed to investigate the survival benefit of eribulin as well as that of taxane-based regimens in Japanese patients with metastatic breast cancer (MBC) in a real-world setting. METHODS:This study enrolled women with MBC who received eribulin or taxane-based regimens with or wi...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章,多中心研究
doi:10.1111/ajco.12863
更新日期:2018-10-01 00:00:00
abstract:PURPOSE:To study trends of urological cancers mortalities in Iran between 1990 and 2015 as a part of a larger project named national and subnational burden of diseases, injuries, and risk factors. METHODS:The primary dataset of this project comprises data of national death registration system. Cause-specific mortality...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 历史文章,杂志文章
doi:10.1111/ajco.13074
更新日期:2019-04-01 00:00:00
abstract:BACKGROUND:The comprehensive genetic alterations underlying the pathogenesis of Sézary syndrome (SS) remains largely unknown. Previous studies showed that alterations of tumor necrosis factor-α-induced protein 3 gene (TNFAIP3; A20) are frequent in SS. In this study, we characterized the mutation and polymorphisms of A2...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12672
更新日期:2018-04-01 00:00:00
abstract:AIMS:Currently, the only standard systemic treatment for advanced hepatocellular carcinoma is sorafenib monotherapy. The study was conducted to assess the efficacy and safety of the novel combination of sorafenib and gemcitabine in the treatment of advanced hepatocellular carcinoma. METHODS:Between March 2008 and Octo...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章,多中心研究
doi:10.1111/ajco.12191
更新日期:2014-09-01 00:00:00
abstract:AIMS:To evaluate the response and progression-free survival (PFS) of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor (EGFR) mutation status treated with gefitinib. METHODS:A retrospective analysis of consecutive patients with EGFR mutation unknown stage III or IV lung ...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/j.1743-7563.2011.01509.x
更新日期:2012-09-01 00:00:00
abstract:AIM:Retroperitoneal sarcomas (RPSs) are large, rare tumors. The role of core biopsy for retroperitoneal masses identified by preoperative imaging is unclear and we report the safety and accuracy of core biopsies at a specialized sarcoma unit in Sydney, Australia. METHODS:A retrospective analysis of a prospectively col...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12125
更新日期:2016-03-01 00:00:00
abstract:AIM:To evaluate the attitudes of patients with different cancers towards research biopsies outside a clinical trial. METHODS:Patients with metastatic cancer completed a questionnaire that assessed patients' willingness to consider research biopsies. Research biopsies were divided into two groups: biopsies performed as...
journal_title:Asia-Pacific journal of clinical oncology
pub_type: 杂志文章
doi:10.1111/ajco.12783
更新日期:2018-06-01 00:00:00